Transporting pharmaceutical and biotech products is a high-stakes operation. Vaccines, biologics, cell and gene therapies, diagnostic reagents, and clinical trial materials often have narrow temperature tolerances and limited shelf lives. A short temperature excursion can compromise efficacy, invalidate trials, or create safety risks for patients. In a global supply chain where shipments cross borders, climates, and handling environments, maintaining stability from origin to destination is a persistent problem.
Dry ice has become one of the most reliable solutions to that problem. By delivering consistent subzero temperatures without liquid residue, it helps protect sensitive products through long journeys and unexpected delays. This article explores the transport challenges faced by pharma and biotech organizations and explains how dry ice addresses them through a practical problem/solution lens.
The Transport Challenge in Pharma and Biotech
The first challenge is temperature sensitivity. Many biologics must remain between −20 °C and −80 °C, while some advanced therapies require even colder conditions. Traditional cold packs struggle to hold these ranges for extended periods, especially during customs clearance or last-mile delivery.
The second challenge is variability. Shipments may move from controlled manufacturing sites to airports, trucks, warehouses, and clinics, each with different environmental conditions. Even brief exposure to warmer air during transfers can trigger degradation.
A third challenge is compliance. Regulations require documented proof that products remained within specified limits throughout transit. Any solution must support monitoring and validation without adding contamination risk.
Finally, logistics teams face operational pressure. Packaging needs to be lightweight, reliable, scalable, and compatible with air transport rules. Refrigeration units and powered containers add cost and complexity, and they are not always available in remote regions.
Why Conventional Cooling Methods Fall Short
Gel packs and phase-change materials are common, but they have limits. They typically maintain temperatures near 0 °C or modestly below, making them unsuitable for deep-freeze requirements. Their cooling power diminishes quickly in long transit windows, and they add significant weight.
Mechanical refrigeration can provide precision, but it introduces dependence on power sources, maintenance, and specialized handling. Any failure can be catastrophic. In contrast, many shipments need a passive solution that works independently of infrastructure.
These gaps have driven the industry toward a solution that is simple, powerful, and predictable.
Dry Ice as a Reliable Cold Chain Solution
Dry ice is solid carbon dioxide that sublimates directly from solid to gas at −78.5 °C. This property makes it ideal for deep-freeze transport. As it sublimates, it absorbs heat, creating a stable cold environment without melting into liquid.
Because it does not leave moisture, dry ice reduces the risk of contamination and packaging damage. Its consistent sublimation rate allows logistics teams to calculate how much is needed for specific transit times and ambient conditions.
Dry ice is also widely available, making it practical for global distribution. When handled correctly, it offers a passive cooling method that does not rely on electricity or complex systems.
Maintaining Ultra-Low Temperatures Over Long Distances
One of the most pressing problems in pharma logistics is maintaining ultra-low temperatures during long shipments. Dry ice solves this by delivering sustained cooling power for days, sometimes weeks, depending on packaging and quantity.
Insulated containers combined with dry ice can keep internal temperatures well below −60 °C, even when external temperatures fluctuate. This stability is crucial for mRNA vaccines, viral vectors, and certain enzymes that degrade rapidly outside strict ranges.
In air transport, where delays are common, dry ice provides a buffer against uncertainty. If a flight is rerouted or held on the tarmac, sublimation continues at a predictable rate, preserving product integrity until delivery resumes.
Reducing Risk During Handling and Transfers
Handling is another weak point in the cold chain. Every transfer increases the chance of temperature excursions. Dry ice mitigates this risk by maintaining a cold micro-environment within the package, even when outer conditions change.
Unlike refrigerated trucks that must be opened for loading and unloading, dry-ice-cooled packages remain sealed. This minimizes exposure and simplifies handoffs between carriers, warehouses, and clinical sites.
Additionally, because dry ice is inert and non-toxic when ventilated properly, it aligns well with clean handling practices required in pharmaceutical logistics.
Supporting Compliance and Traceability
Regulatory compliance demands proof of temperature control. Dry ice solutions are commonly paired with data loggers that record internal conditions throughout the journey. The predictable thermal behavior of dry ice makes deviations easier to identify and investigate.
This traceability supports audits and quality assurance processes. When shipments arrive with complete temperature histories, organizations can release products with confidence, reducing waste and delays.
By lowering the frequency of temperature excursions, dry ice indirectly reduces the number of deviations that must be reported and managed, easing the compliance burden.
Flexibility for Different Product Profiles
Not all pharma and biotech products have the same needs. Some require ultra-low temperatures, others moderate freezing, and some need protection only during specific legs of the journey. Dry ice can be tailored to these profiles by adjusting quantity, container design, and insulation.
This flexibility is especially valuable in clinical trials, where small batches move frequently between sites. Dry ice packaging can be scaled up or down without redesigning the entire logistics process.
It also supports hybrid strategies, where dry ice is used alongside other cooling methods to optimize cost and performance.
Safety Considerations and Best Practices
While dry ice is effective, it requires proper handling. Because it sublimates into carbon dioxide gas, ventilation is essential to prevent pressure buildup or oxygen displacement. Packaging is designed with vents to allow gas to escape safely.
Clear labeling and training help ensure compliance with transport regulations, particularly in air freight. When best practices are followed, dry ice is a safe and dependable component of the cold chain.
These safety protocols are well established, making dry ice a mature solution rather than an experimental one.
Beyond Transport: A Broader Role in Clean Operations
Dry ice is best known for cooling, but its properties also support cleanliness in pharma environments. Techniques like dry ice blasting are used in facilities to clean equipment without water or chemicals, reducing contamination risks and downtime. While this application is separate from transport, it reflects the broader value of dry ice in maintaining controlled, sterile conditions across the product lifecycle.
This dual role reinforces confidence in dry ice as a material that aligns with the strict standards of pharmaceutical and biotech operations.
Cost Efficiency and Sustainability Considerations
Cost control is an ongoing challenge in cold chain logistics. Dry ice offers a favorable balance between performance and expense. It eliminates the need for powered refrigeration in many scenarios and reduces losses from spoiled products.
From a sustainability perspective, dry ice used in transport is often captured as a byproduct from industrial processes, meaning it does not necessarily add new carbon dioxide to the atmosphere. Its efficient cooling can also reduce the need for heavier packaging and repeated shipments, indirectly lowering environmental impact.
Adapting to a Growing and Complex Supply Chain
As personalized medicine, biologics, and global clinical trials expand, the complexity of the supply chain increases. Dry ice scales with this growth. It can be deployed quickly in emerging markets, supports decentralized manufacturing models, and adapts to evolving regulatory requirements.
By addressing the core problems of temperature control, reliability, and compliance, dry ice enables innovation without compromising safety.
